PPARG and neurodegenerative disease: The potent neuroprotective activity of NF-α1-CPE, or the PPARγ agonist, rosiglitazone which up-regulates NF-α1-CPE expression in mouse hippocampus12,44, renders them as potentially useful therapeutic agents for treating neurodegenerative diseases as suggested by a pilot clinical study45.